Pharmaceuticals

Short-Acting Insulin Market Forecast 2025–2034: Where Businesses Should Invest Next

November 11, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Short-Acting Insulin Market By 2029?

The short-acting insulin market size has shown steady expansion in recent years. It is anticipated to increase from $11 billion in 2024 to reach $11.54 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 4.8%. This growth observed in the past can be attributed to factors such as an expanding population of individuals with type 1 diabetes, an aging demographic, a rise in research and development investments, the widespread occurrence of diagnosed cases, and increasing urbanization.

The short-acting insulin market is projected to experience substantial expansion over the upcoming years, reaching “$14.14 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period can be primarily attributed to several factors: a surge in governmental initiatives and support, rapid advancements in manufacturing processes, the growing acceptance of insulin therapy, and the emergence of personalized medicine. Key trends anticipated during this period encompass progress in insulin delivery devices and associated technologies, the introduction of innovative fast-acting insulin analogs, the continuous development of biosimilars, a noticeable shift towards patient-focused care, and improvements in formulation techniques.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Major Market Drivers Are Shaping The Future Of The Short-Acting Insulin Market?

The growing occurrence of Type 1 diabetes is projected to boost the expansion of the short-acting insulin market in the future. Type 1 diabetes represents an autoimmune ailment characterized by the immune system attacking insulin-generating cells, necessitating continuous insulin treatment. The increasing incidence of Type 1 diabetes stems from genetic predispositions, environmental factors, and a rise in autoimmune conditions. Short-acting insulin assists in managing Type 1 diabetes by offering prompt regulation of blood sugar levels and emulating the body’s natural insulin action. As an illustration, data from Diabetes Australia, an Australian organization dedicated to diabetes awareness, indicated that in 2022, around 134,000 Australians had Type 1 diabetes. This number saw an increase, reaching 135,423 in 2023. Consequently, the escalating prevalence of Type 1 diabetes is propelling the growth of the short-acting insulin market.

Which Key Segments Fueling The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Are The Major Trends Driving The Growth Of The Short-Acting Insulin Market?

Major companies active in the short-acting insulin market are focusing on innovative products, such as insulin pods, to provide continuous insulin infusion and adherence for individuals with diabetes. An insulin pod is defined as a tubeless, wearable insulin delivery system that offers continuous insulin infusion for diabetes management. For instance, in April 2023, Insulet Corporation, a US-based medical device company, announced U.S. Food and Drug Administration (FDA) clearance for Omnipod GO, a groundbreaking basal-only insulin pod specifically designed for adults with type 2 diabetes. This tubeless, wearable device ensures continuous insulin delivery without requiring a separate controller. Omnipod GO simplifies diabetes management by eliminating daily injections and providing pre-programmed insulin rates. With its user-friendly design and pharmacy accessibility, it enhances convenience for both patients and healthcare providers. This launch reinforces Insulet’s commitment to improving diabetes care through innovative technology.

Which Key Market Players Are Investing In Expansion And Innovation Of Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Short-Acting Insulin Market?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2025, By The Business Research Company

Insulin Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Smart Insulin Pens Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

Insulin Pens Syringes Pumps And Injectors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-pens-syringes-pumps-and-injectors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795